What is Esperion Therapeutics's net debt / EBITDA?

Esperion Therapeutics (ESPR) reported net debt / EBITDA of -0× in Q1 2026.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Esperion Therapeutics ESPR Net debt / EBITDA

Net debt / EBITDA at other companies

AmgenAMGN

3.7×-0.7×

Regeneron PharmaceuticalsREGN

-0.1×0.0×

Eton Pharmaceuticals, Inc.ETON

7.6×—

Zevra Therapeutics, Inc.ZVRA

-35.8×—

OrganonOGN

6×+0.4×

ViatrisVTRS

4.3×—

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Calculated from Esperion Therapeutics’s reported figures.

net debt/ebitda=-0×

Based on the most recent quarter.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's net debt / EBITDA?: Esperion Therapeutics (ESPR) reported net debt / EBITDA of -0× in Q1 2026.
What does net debt / EBITDA mean?: Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.